X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients

By Nicole Longo  |    December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...   Read More

340B hospitals and for-profit pharmacies generating significant revenue from program meant to help needy patients

By Nicole Longo  |    October 23, 2020
The 340B program – a safety-net federal drug program meant to help vulnerable Americans – has become dominated by many large hospitals and for-profit corporations with no clear evidence they are...   Read More

Growth in 340B program has not translated to improvements for patients

By Nicole Longo  |    October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....   Read More

New GAO report: Some hospitals participating in 340B may not be eligible for the program

By Nicole Longo  |    January 14, 2020
The Government Accountability Office (GAO) released a new report on 340B hospital eligibility compliance and made a number of alarming observations that underscore the need for more accountability in...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals

By Nicole Longo  |    May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little has...   Read More

340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings

By Nicole Longo  |    April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build on...   Read More

New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program

By Nicole Longo  |    December 18, 2018
Data and analyses continue to show the 340B program influences prescribing trends at 340B hospitals – ultimately costing patients and our health care system more money. The Government Accountability...   Read More

New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending

By Nicole Longo  |    August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...   Read More

GAO again recommends improvements to 340B program

By Nicole Longo  |    July 11, 2018
Over the years, the non-partisan Government Accountability Office (GAO) has reviewed various aspects of the 340B program, finding areas for improvement and providing recommendations. The latest...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."